MGNX vs. BMY
Compare and contrast key facts about MacroGenics, Inc. (MGNX) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: MGNX or BMY.
Correlation
The correlation between MGNX and BMY is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
MGNX vs. BMY - Performance Comparison
Key characteristics
MGNX:
-0.71
BMY:
0.58
MGNX:
-0.73
BMY:
1.09
MGNX:
0.87
BMY:
1.14
MGNX:
-0.89
BMY:
0.35
MGNX:
-1.14
BMY:
1.46
MGNX:
73.16%
BMY:
11.59%
MGNX:
117.00%
BMY:
29.25%
MGNX:
-94.40%
BMY:
-70.62%
MGNX:
-92.89%
BMY:
-26.20%
Fundamentals
MGNX:
$179.50M
BMY:
$110.46B
MGNX:
-$1.57
BMY:
-$4.41
MGNX:
0.01
BMY:
1.19
MGNX:
$130.61M
BMY:
$48.30B
MGNX:
$120.15M
BMY:
$32.20B
MGNX:
-$44.92M
BMY:
$3.16B
Returns By Period
In the year-to-date period, MGNX achieves a -12.00% return, which is significantly lower than BMY's -2.70% return. Over the past 10 years, MGNX has underperformed BMY with an annualized return of -22.40%, while BMY has yielded a comparatively higher 2.13% annualized return.
MGNX
-12.00%
-4.67%
-20.99%
-83.45%
-24.38%
-22.40%
BMY
-2.70%
-3.30%
13.61%
14.62%
0.01%
2.13%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
MGNX vs. BMY — Risk-Adjusted Performance Rank
MGNX
BMY
MGNX vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for MacroGenics, Inc. (MGNX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
MGNX vs. BMY - Dividend Comparison
MGNX has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.45%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MGNX MacroGenics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.45% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
MGNX vs. BMY - Drawdown Comparison
The maximum MGNX drawdown since its inception was -94.40%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for MGNX and BMY. For additional features, visit the drawdowns tool.
Volatility
MGNX vs. BMY - Volatility Comparison
MacroGenics, Inc. (MGNX) has a higher volatility of 20.09% compared to Bristol-Myers Squibb Company (BMY) at 8.59%. This indicates that MGNX's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
MGNX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between MacroGenics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities